Fulcrum Therapeutics (FULC) Amortizatization of Intangibles (2020 - 2026)
Fulcrum Therapeutics (FULC) reported Amortizatization of Intangibles of $767000.0 for Q1 2026, down 14.68% year-over-year from $899000.0 in Q1 2025, and up 100.26% quarter-over-quarter from $383000.0 in Q4 2025.
Fulcrum Therapeutics (FULC) Amortizatization of Intangibles (2020 - 2026) Analysis & Trends
Fulcrum Therapeutics (FULC) has 7 years of Amortizatization of Intangibles data on file, last reported at $767000.0 in Q1 2026.
- Amortizatization of Intangibles for Q1 2026 came in at $767000.0, down 14.68% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.8 million (down 31.69% YoY), and the FY2025 annual result was $3.0 million, down 32.76% from the prior year.
- Amortizatization of Intangibles advanced to $767000.0 in Q1 2026 per FULC's latest filing, from $383000.0 in the prior quarter.
- Over five years, Amortizatization of Intangibles peaked at $1.7 million in Q2 2023 and troughed at -$353000.0 in Q1 2022.
- A 5-year average of $820647.1 and a median of $945000.0 in 2024 frame the typical range for Amortizatization of Intangibles.
- The sharpest annual moves came in 2022 and 2023: Amortizatization of Intangibles tumbled 377.03% in 2022, then jumped 1515.18% in 2023.
- A 5-year view of Amortizatization of Intangibles shows it stood at $601000.0 in 2022, then soared by 120.97% to $1.3 million in 2023, then declined by 28.84% to $945000.0 in 2024, then slumped by 59.47% to $383000.0 in 2025, then jumped by 100.26% to $767000.0 in 2026.
- Business Quant data shows FULC's Amortizatization of Intangibles at $767000.0 in Q1 2026, $383000.0 in Q4 2025, and $586000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 13,267.00 |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | Fulcrum Therapeutics | 267.90 Mn | 267.90 Mn | - | 767,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 767,000.00 |
| Mar 31, 2026 | 767,000.00 |
| Dec 31, 2025 | 383,000.00 |
| Dec 31, 2025 | 383,000.00 |
| Sep 30, 2025 | 586,000.00 |
| Sep 30, 2025 | 586,000.00 |
| Jun 30, 2025 | 1.09 Mn |
| Jun 30, 2025 | 1.09 Mn |
| Mar 31, 2025 | 899,000.00 |
| Mar 31, 2025 | 899,000.00 |
| Dec 31, 2024 | 945,000.00 |
| Dec 31, 2024 | 945,000.00 |
| Sep 30, 2024 | 1.15 Mn |
| Sep 30, 2024 | 1.15 Mn |
| Jun 30, 2024 | 1.13 Mn |
| Jun 30, 2024 | 1.13 Mn |
| Mar 31, 2024 | 1.16 Mn |
| Mar 31, 2024 | 1.16 Mn |
| Dec 31, 2023 | 1.33 Mn |
| Dec 31, 2023 | 1.33 Mn |